5 questions ESMO cancer drug data might answer
Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! Dive Brief: Eli Lilly's Lartruvo failed a Phase 3 study in advanced or metastatic soft tissue sarcoma, an indication for which it gained accelerated approval back in October 2016. More specifically, regulators cleared Lartruvo in combination with standard-of-care chemotherapy for … Συνεχίστε να διαβάζετε Lilly suspends Lartruvo promotion after Phase 3 failure.
Who’s the Boss? Companies and Their Novel Drug Approvals, 2014-2018
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
As Novartis' other cancer launches struggle, Lutathera gets off to flying start
Pfizer works to get 'wait-and-see' doctors on board the Ibrance train
Viagra no more: The changing face of drug ads on TV
Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because new rivals are stealing its share. The fast-growing blockbuster still boasts a 91% share of the CDK 4/6 class, CEO Ian Read told investors on Pfizer’s quarterly conference call, despite new competition from Novartis’ Kisqali and Eli Lilly’s Verzenio. The shortfall performance “has … Συνεχίστε να διαβάζετε A slowing market—not new rivals—is hurting Pfizer’s star cancer med Ibrance, executives say.
Less than one day after Novartis CEO Vas Narasimhan talked up a potential key approval for lagging breast cancer drug Kisqali, the company has that approval in hand. The FDA go-ahead gives Kisqali “the broadest first-line indications of any” member of the CDK 4/6 class, which also includes Pfizer blockbuster Ibrance and Eli Lilly … Συνεχίστε να διαβάζετε Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali.
Fresh from the annual meeting of the American Society of Clinical Oncology in Chicago where pharmaceutical companies highlighted their pipelines and products, what is the outlook for the cancer-drug market, the largest therapeutic area in the global pharmaceutical industry? DCAT Value Chain Insights takes an inside look. The global oncology-drug market reached $133 billion in 2017. … Συνεχίστε να διαβάζετε Strong Growth for the Oncology-Drug Market.